<DOC>
	<DOCNO>NCT02981069</DOCNO>
	<brief_summary>In study , researcher hope learn SGLT2 inhibition EGP ( endogenous glucose production ) plasma glucose concentration diabetic subject . Researchers examine diabetes role increase plasma glucagon , decline plasma insulin , fall plasma glucose concentration .</brief_summary>
	<brief_title>Effect GLP-1 Receptor Agonist , Exenatide Glucosuria Induced Elevation ENDOGENOUS GLUCOSE PRODUCTION ( EGP )</brief_title>
	<detailed_description>This study examine whether coadministration exenatide plus dapagliflozin prevent increase EGP result additive even synergistic decrease plasma glucose concentration compare agent alone .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>BMI = 2535 kg/m^2 must drug naïve and/or stable dose ( 3 month ) metformin and/or sulfonylurea HbA1c &gt; 7.0 % &lt; 10.0 % Other diabetes , subject must good general health determine physical exam , medical history , blood chemistry , CBC , TSH , T4 , EKG urinanalysis . Only subject whose body weight stable ( ± 3 lb ) precede three month participate excessively heavy exercise program include . Subjects take drug know affect glucose metabolism ( metformin sulfonylurea ) exclude Individuals evidence proliferative diabetic retinopathy , plasma creatinine &gt; 1.4 female &gt; 1.5 male , 24hour urine albumin excretion &gt; 300 mg exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>